Compositions and methods for detecting or quantifying Hepatitis B virus
View Patent ↗This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis B virus (HBV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the P and/or S open reading frames of HBV and are configured to provide substantially equivalent quantification of different genotypes and variants of HBV.
1. An amplification oligomer comprising the sequence of SEQ ID NO: 2.
2. A kit comprising a first amplification oligomer which is the amplification oligomer of claim 1 , and a second amplification oligomer comprising at least 14 contiguous nucleotides of Hepatitis B virus (HBV) sequence of a genotype, subtype, or isolate of HBV, wherein the first and second amplification oligomers are configured to produce an amplicon in the presence of an HBV nucleic acid.
3. The kit of claim 2 , wherein the second amplification oligomer comprises the sequence of any one of SEQ ID NOs: 20, 21, or 22.
4. A kit comprising a first amplification oligomer which is the amplification oligomer of claim 1 , and a second amplification oligomer, wherein the second amplification oligomer comprises at least 10 contiguous nucleotides of one of SEQ ID NOs: 20, 21, or 22, and wherein the first and second amplification oligomers are configured to produce an amplicon in the presence of an HBV nucleic acid.
5. The kit of claim 2 , further comprising third and fourth amplification oligomers configured to produce an amplicon in the presence of an HBV nucleic acid, wherein the fourth amplification oligomer comprises at least 10 contiguous nucleotides of SEQ ID NO: 35 including the inosine at position 30 of SEQ ID NO: 35 and at least 14 contiguous nucleotides of Hepatitis B virus sequence of a genotype, subtype, or isolate of HBV.
6. A method of detecting the presence or absence of Hepatitis B virus in a sample, comprising:
contacting the sample with at least the amplification oligomer of claim 1 and a second amplification oligomer, the second amplification oligomer comprising at least 14 contiguous nucleotides of Hepatitis B virus (HBV) sequence of a genotype, subtype, or isolate of HBV, wherein the first and second amplification oligomers are configured to produce an amplicon in the presence of an HBV nucleic acid; and
performing a nucleic acid amplification reaction which produces the amplicon in the presence of the HBV nucleic acid.
7. The method of claim 6 , wherein the second amplification oligomer comprises the sequence of any one of SEQ ID NOs: 20, 21, or 22.
8. An amplification oligomer comprising (i) at least 10 contiguous nucleotides of SEQ ID NO: 35, wherein one of the at least 10 contiguous nucleotides of SEQ ID NO: 35 is the inosine at position 30 of SEQ ID NO: 35, and (ii) at least 14 contiguous nucleotides of HBV sequence of a genotype, subtype, or isolate of HBV.
9. The amplification oligomer of claim 8 , comprising at least 14 contiguous nucleotides of SEQ ID NO: 35 including the inosine at position 30 of SEQ ID NO: 35.
10. The amplification oligomer of claim 8 , comprising at least 18 contiguous nucleotides of SEQ ID NO: 35 including the inosine at position 30 of SEQ ID NO: 35.
11. The amplification oligomer of claim 8 , comprising the sequence of SEQ ID NO: 35.
12. A kit comprising a pair of amplification oligomers, the pair comprising the amplification oligomer of claim 8 and a second amplification oligomer comprising at least 14 contiguous nucleotides of Hepatitis B virus sequence of a genotype, subtype, or isolate of HBV, wherein the pair of amplification oligomers is configured to produce an amplicon in the presence of a Hepatitis B virus nucleic acid.
13. The kit of claim 12 , wherein the second amplification oligomer comprises the sequence of SEQ ID NO: 41.
14. A kit comprising a pair of amplification oligomers, the pair comprising the amplification oligomer of claim 8 and a second amplification oligomer, wherein the second amplification oligomer comprises at least 10 contiguous nucleotides of SEQ ID NO: 41, and wherein the pair of amplification oligomers is configured to produce an amplicon in the presence of a Hepatitis B virus nucleic acid.
15. A method of detecting Hepatitis B virus in a sample, comprising:
contacting the sample with at least the amplification oligomer of claim 8 and an oppositely oriented amplification oligomer, the oppositely oriented amplification oligomer comprising at least 14 contiguous nucleotides of Hepatitis B virus (HBV) sequence of a genotype, subtype, or isolate of HBV, wherein the first and second amplification oligomers are configured to produce an amplicon in the presence of an HBV nucleic acid; and
performing a nucleic acid amplification reaction which produces the amplicon in the presence of the HBV nucleic acid.
16. A probe oligomer comprising the sequence of SEQ ID NO: 29, wherein the sequence of SEQ ID NO: 29 includes a c9 linker between nucleotides 33 and 34 of SEQ ID NO: 29.
17. The probe oligomer of claim 16 , further comprising a fluorescent label.
18. The probe oligomer of claim 17 , further comprising a quencher, wherein the quencher absorbs fluorescence to a greater extent when the probe is free than when the probe is annealed to a target nucleic acid.
19. A kit comprising the probe oligomer of claim 16 and amplification oligomers, wherein the amplification oligomers comprise a pair of amplification oligomers configured to produce an amplicon in the presence of an HBV nucleic acid, the amplicon comprising a target sequence recognized by the probe oligomer.
20. The kit of claim 19 , wherein the amplification oligomers comprise (i) an amplification oligomer comprising the sequence of SEQ ID NO: 2 and a second amplification oligomer; or (ii) an amplification oligomer comprising at least 10 contiguous nucleotides of SEQ ID NO: 35 including the inosine at position 30 of SEQ ID NO: 35 and at least 14 contiguous nucleotides of HBV sequence of a genotype, subtype, or isolate of HBV.
21. A method of detecting an HBV nucleic acid, comprising contacting the HBV nucleic acid with the probe oligomer of claim 16 and detecting the formation of a complex comprising the HBV nucleic acid and the probe oligomer.
22. The method of claim 21 , wherein the HBV nucleic acid is an amplicon, and the method further comprises producing the amplicon using amplification oligomers, wherein the amplification oligomers comprise (i)(a) an amplification oligomer comprising the sequence of SEQ ID NO: 2 and (b) a second amplification oligomer; or (ii)(a) an amplification oligomer comprising at least 10 contiguous nucleotides of SEQ ID NO: 35 including the inosine at position 30 of SEQ ID NO: 35 and at least 14 contiguous nucleotides of HBV sequence of a genotype, subtype, or isolate of HBV and (ii) a second amplification oligomer.